Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8IYD8
UPID:
FANCM_HUMAN
Alternative names:
ATP-dependent RNA helicase FANCM; Fanconi anemia-associated polypeptide of 250 kDa; Protein Hef ortholog
Alternative UPACC:
Q8IYD8; B2RTQ9; Q3YFH9; Q8N9X6; Q9HCH6
Background:
The Fanconi anemia group M protein, also known as ATP-dependent RNA helicase FANCM, plays a crucial role in DNA repair. It is a key component of the Fanconi anemia (FA) core complex, essential for the activation of the FA pathway, which is critical for cellular resistance to DNA cross-linking drugs and the prevention of chromosomal breakage.
Therapeutic significance:
FANCM is linked to Spermatogenic failure 28 and Premature ovarian failure 15, both genetic disorders affecting fertility. Understanding the role of Fanconi anemia group M protein could open doors to potential therapeutic strategies for these conditions.